Avalo Therapeutics (AVTX) announced the appointment of Michael Heffernan as Chairman of the Board of Directors. Heffernan will succeed Dr. Garry Neil as Chairman of the Board. Dr. Neil will continue as a Board member and Chief Executive Officer of the Company.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AVTX:
- Avalo Therapeutics initiated with a Buy at Stifel
- Avalo Therapeutics initiated with a Buy at Jefferies
- Promising Outlook for Avalo Therapeutics’ AVTX-009 in HS Treatment
- Promising Investment Opportunity in Avalo Therapeutics: Strong Financial Position and Breakthrough HS Treatment
- Avalo Therapeutics reports FY24 EPS ($20.91) vs ($113.58) last year